(Q35586775)

9 August 2017

1 reference

title

Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen (English)

1 reference

9 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

3 April 2024

author name string

M. Dowsett

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623519

3 April 2024

B. P. Haynes

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623519

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623519

3 April 2024

publication date

1 September 2003

1 reference

full work available at URL

9 August 2017

https://api.elsevier.com/content/article/PII:S0960076003003650?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

https://api.elsevier.com/content/article/PII:S0960076003003650?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

The Journal of Steroid Biochemistry and Molecular Biology

3 April 2024

published in

1 reference

9 August 2017

volume

86

1 reference

9 August 2017

issue

3-5

1 reference

9 August 2017

page(s)

255-263

1 reference

Aromatase inhibitors in breast cancer therapy

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Comprehensive pharmacology and clinical efficacy of aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Comparison of the Low Dose Short Synacthen Test (1 g), the Conventional Dose Short Synacthen Test (250 g), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients with Pituitary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Establishment of reference values for standard dose short synacthen test (250 microgram), low dose short synacthen test (1 microgram) and insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

The short Synacthen and insulin stress tests in the assessment of the hypothalamic-pituitary-adrenal axis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

The use of the short tetracosactrin test for the investigation of suspected pituitary hypofunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Resistance of the ovary to blockade of aromatization with aminoglutethimide

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Effect of estrogen deprivation on the reproductive physiology of male and female primates

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Tamoxifen metabolism: pharmacokinetic and in vitro study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Determination of tamoxifen and five metabolites in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Identification and biological activity of tamoxifen metabolites in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Hydroxy derivatives of tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Estrone and estradiol content in human breast tumors: Relationship to estradiol receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900365-0

7 January 2021

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

7

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer

3 April 2024

33

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment

3 April 2024

38

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

The bioavailability of Tamoplex (tamoxifen). Part 3. A steady-state study in breast cancer patients

3 April 2024

41

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

The bioavailability of Tamoplex (tamoxifen). Part 1. A pilot study

3 April 2024

43

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue

3 April 2024

60

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00365-0

3 April 2024

Identifiers

1 reference

9 August 2017

1 reference